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Abstract
OBJECTIVES: Primary graft dysfunction (PGD) is a major cause of early morbidity and mortality after cadaveric lung transplantation (CLT).
This study examined the incidence, time course and predictive value of PGD after living-donor lobar lung transplantation (LDLLT).
METHODS: We retrospectively investigated 75 patients (42 with LDLLT and 33 with CLT) who underwent lung transplantation from January
2008 to December 2013. Patients were assigned PGD grades at six time points, as defined by the International Society for Heart and Lung
Transplantation: immediately after final reperfusion, upon arrival at the intensive care unit (ICU), and 12, 24, 48 and 72 h after ICU admission.
RESULTS: The incidence of severe (Grade 3) PGD at 48 or 72 h after ICU admission was similar for LDLLT and CLT patients (16.7 vs 12.1%;
P = 0.581). The majority of the LDLLT patients having severe PGD first developed PGD immediately after reperfusion, whereas more than half
of the CLT patients first developed severe PGD upon ICU arrival or later. In LDLLT patients, severe PGD immediately after reperfusion was
significantly associated with fewer ventilator-free days during the first 28 postoperative days [median (interquartile range) of 0 (0–10) vs 21
(13–25) days, P = 0.001], prolonged postoperative ICU stay [median (interquartile range) of 20 (16–27) vs 12 (8–14) days, P = 0.005] and
increased hospital mortality (27.3 vs 3.2%, P = 0.02). Severe PGD immediately after reperfusion was not associated with ventilator-free days
during the first 28 postoperative days, time to discharge from ICU or hospital, or hospital mortality in CLT patients.
CONCLUSIONS: Postoperative incidence of severe PGD was not significantly different between LDLLT and CLT patients. In LDLLT patients, the
onset of severe PGD tended to be earlier than that in CLT patients. Severe PGD immediately after reperfusion was a significant predictor of
postoperative morbidity and mortality in LDLLT patients but not in CLT patients.
Keywords: Living-donor lobar lung transplantation • Cadaveric lung transplantation • Primary graft dysfunction • Reperfusion injury •
Postoperative complications • Hospital mortality
INTRODUCTION
Living-donor lobar lung transplantation (LDLLT) was first performed
in the 1990s in response to a mismatch between the supply and
demand for donor lungs from brain-dead donors [1]. We recently
demonstrated that survival following LDLLT is similar to that observed
for cadaveric lung transplantation (CLT), despite the worse preopera-
tive condition of LDLLT patients, and the use of LDLLT as a viable
option in patients who may not survive a long waiting period for ca-
daveric donors [2]. In contrast, our analysis revealed that LDLLT
patients require a greater duration of postoperative mechanical ven-
tilation than CLT patients, probably due to the poorer preoperative
condition of LDLLT patients. Early identification of patients with a
poor postoperative course following LDLLT may help optimize post-
operative management strategies, including the alteration of ventila-
tion modalities or pharmacological agents [3–5].
Primary graft dysfunction (PGD), a form of acute lung injury oc-
curring after lung transplantation [3, 6, 7], is known to significantly
impact postoperative morbidity and mortality following lung
transplantation. Severe PGD is associated with delayed extubation,
prolonged stays in both intensive care and hospital, increased
early mortality and worsened long-term outcomes in transplant
survivors [6, 8–12]. In 2005, the International Society for Heart and
Lung Transplantation (ISHLT) proposed a standardized definition
of PGD [11], with subsequent studies validating this definition with
data regarding clinical outcomes [13, 14]. However, each of these
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studies involved CLT patients only. We previously reported severe
PGD requiring extracorporeal membrane oxygenation (ECMO) in
4 of 14 LDLLT patients receiving grafts from a single donor [15].
However, the incidence of PGD after LDLLT according to ISHLT
criteria is currently unknown, and the prognostic value of PGD in
LDLLT has yet to be elucidated.
The purpose of this single-centre retrospective study was to
examine the incidence and time course of PGD after LDLLT, and
to assess the impact of PGD on outcomes in LDLLT patients.
MATERIALS ANDMETHODS
This retrospective cohort study was approved by the ethics commit-
tee of Kyoto University Hospital (approval number: E2080). All
patients who underwent lung transplantation (LDLLT or CLT) at
Kyoto University Hospital from 1 January 2008 to 31 December
2013 were eligible for this study. The medical records of eligible
patients were reviewed with regard to patient characteristics, pre-
operative examination, and intra- and postoperative clinical course.
In Japan, all patients requiring CLT from brain-dead donors are
registered at the Japan Organ Transplantation Network. The organ
allocation process for CLT is largely based on the accrued time on
the waiting list. The indications and size-matching criteria for
LDLLT were described previously [2, 16]. Indication for LDLLT was
limited to critically ill patients unlikely to survive waiting for cadav-
eric lungs. In LDLLT, graft forced vital capacity (FVC) was calculated
using the following equation: (graft FVC) = (number of resected
segments)/19. We accepted a size disparity when the graft FVC
was 45% or more of the predicted FVC of the recipient (calculated
according to height, age and gender).
Perioperative management was essentially identical for LDLLT
and CLT patients. Although attending anaesthesiologists were re-
sponsible for ventilation during general anaesthesia, a positive
end-expiratory pressure of 5 cmH2O or greater was used following
reperfusion in all cases. Postoperative respiratory management
was performed according to a common protocol as previously
described [17]. In brief, all patients were transferred to the inten-
sive care unit (ICU) after lung transplantation, intubated and
placed on artificial ventilation (Puritan Benett™ 840 Ventilator
System: Covidien Japan, Tokyo, Japan) for at least 2 days post-
operatively. From postoperative day 2, extubation was considered
under the following circumstances: (i) stable vital signs with a
PaO2=FIO2 ratio ≥200; (ii) stable underlying disease and complica-
tions; (iii) minimal artificial ventilation support; and (iv) sufficient
spontaneous breathing. Tracheostomy was performed in all cases
where prolonged artificial ventilation was necessary. Patients were
considered for discharge from the ICU when haemodynamically
stable, following extubation or tracheostomy.
Patients were assigned PGD grades at six time points according
to the ISHLT definition of PGD: Immediately after final reperfusion
(Trep), upon at ICU arrival (T0) and 12 h (T12), 24 h (T24), 48 h
(T48) and 72 h (T72) after ICU admission (11). In brief, a PaO2=FIO2
ratio >300 was defined as Grade 0–1; a PaO2=FIO2 ≥200 and ≤0300
as Grade 2; and a PaO2=FIO2 <200 as Grade 3. Although the ISHLT
PGD definitions divide patients with a PaO2=FIO2 >300 into two
groups (Grade 0 and Grade 1) on the basis of the presence or
absence of radiographic infiltrates, we classified any patient with a
PaO2=FIO2 >300 as having Grade 0–1 PGD. Patients who were extu-
bated were also classified as having Grade 0–1 PGD. Patients re-
ceiving ECMO were automatically classified as having Grade 3
PGD while receiving support.
When analysing the impact of PGD on outcomes, PGD Grades
0–1 and 2 were combined, and outcome measures were com-
pared between patients with Grades 0–2 PGD and those with
Grade 3 PGD. The primary outcome was defined as the number of
days of unassisted breathing [ventilator-free days (VFDs)] during
the initial 28 postoperative days. Patients who died or underwent
retransplantation due to graft dysfunction during the initial 28
postoperative days were assigned 0 VFDs [18]. Unassisted breath-
ing was defined as a period lasting at least 48 consecutive hours
beginning with extubation (or removal of ventilatory support for
patients with tracheostomies). Secondary outcomes included time
to ICU and hospital discharge and hospital mortality.
Statistical analysis
Data were analysed using the statistical program R (http://cran.
r-project.org). All data are presented as median (interquartile range)
and number (percentage), unless stated otherwise. Differences
between groups were compared using the Mann–Whitney U-test for
continuous variables. For categorical variables, Pearson’s χ2-test or
Fisher’s exact test were used where appropriate. All statistical tests
were two-tailed. Except for multivariate models, statistical signifi-
cance was set at P < 0.05. Time-to-event analyses were used to
compare lengths of ICU and hospital stays. Patient data were cen-
sored at the time of death or retransplantation. Medians and inter-
quartile range were obtained using Kaplan–Meier analyses, and the
log-rank test was used to assess differences between groups.
Multivariate regression analysis was used to evaluate the independ-
ent role of Grade 3 PGD at Trep in predicting VFDs following LDLLT.
All candidate covariates were included in multivariate analysis with a
backward stepwise elimination performed to identify factors inde-
pendently associated with VFDs. All variables maintaining a P-value
<0.1 were included in the final model. Grade 3 PGD at Trep was
included in all logistic models regardless of statistical significance as
this was the primary variable of interest.
RESULTS
Patient characteristics and operative variables
A total of 75 lung transplantations (42 LDLLTs and 33 CLTs) were per-
formed during the study period. Preoperative patient characteristics
and operative variables are listed in Table 1. Although median ages
were similar between LDLLT and CLT, 11 children under 15 years old
underwent LDLLT, whereas no children underwent CLT. Dyspnoea,
determined according to the Hugh-Jones classification, was signifi-
cantly worse among LDLLT patients (P = 0.005), and the proportion
of ventilator-dependent LDLLT patients tended to be higher (11.9 vs
3.0%, P = 0.1597). All patients required cardiopulmonary support
during LDLLT; however, more than half (51.5%) of patients under-
went CLT without cardiopulmonary support. The total ischaemic
time was significantly shorter in LDLLT than that in CLT (P < 0.0001).
A median graft FVC of 60.0% was observed in LDLLT patients and
was found to be <55% in 15 patients (35.7%).
Prevalence and severity of primary graft
dysfunction
The distribution of patients according to assigned PGD grades at
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least one period of Grade 3 PGD between Trep and T72 was
33.3% in LDLLT patients and tended to be lower than that in CLT
patients (51.5%; P = 0.113). In LDLLT, 11 (26.2%) patients exhibited
Grade 3 PGD at Trep with the incidence of Grade 3 PGD gradually
decreasing thereafter. In CLT, 9 (27.2%) patients exhibited Grade 3
PGD at Trep, with the incidence of Grade 3 PGD highest at T0
(36.4%) and decreasing thereafter. The incidence of Grade 3 PGD
at T48 or T72 was similar between LDLLT and CLT (16.7 vs 12.1%;
P = 0.581) patients. Individual analyses at each time point revealed
that the incidence of Grade 3 PGD was similar between LDLLT
patients and CLT patients, except at T0, where the incidence of
Grade 3 PGD tended to be higher in CLT patients than in LDLLT
patients (36.4 vs 16.7%; P = 0.0645).
We further examined the timing of Grade 3 PGD onset. Among
LDLLT patients, the majority of patients (72.7%) who experienced
Grade 3 PGD developed Grade 3 PGD at Trep. Conversely, more
than half (61.5%) of the CLT patients developed Grade 3 PGD at T0
or T12 (Fig. 2A). The presence of Grade 3 PGD at Trep was signifi-
cantly associated with Grade 3 PGD at T48 or T72 in LDLLT
patients (P < 0.0001); however, this association was not observed
in CLT patients (P = 0.913; Fig. 2B and C).
Impact of Grade 3 primary graft dysfunction on
ventilator-free days
Next, we investigated the impact of Grade 3 PGD at six study
time points on VFDs during the initial 28 postoperative days
(Table 2). Grade 3 PGD at all time points, including Trep, was
strongly associated with decreased VFDs in LDLLT patients. In
contrast, in CLT patients, Grade 3 PGD at Trep was not signifi-
cantly associated with VFDs. Grade 3 PGD at T0 or later was sig-
nificantly associated with VFDs in CLT patients, and the
difference in median VFDs between Grades 0–2 and Grade 3
PGD was the greatest at T48 and T72. Six among 11 (54.6%)
LDLLT patients with Grade 3 PGD at Trep had 0 VFDs; in con-
trast, 7 among 9 CLT patients (77.8%) with Grade 3 PGD at Trep
successfully weaned off from ventilator support within 14 post-
operative days. As the impact of Grade 3 PGD on VFDs was
similar across time points in LDLLT patients, Grade 3 PGD at
Trep was used in subsequent analyses.
Table 1: Preoperative patient characteristics and operative variables
LDLLT (n = 42) CLT (n = 33) P-value
Age (years) 44 (12–55) 40 (29–52) 0.873
Female gender 24 (57.1%) 12 (36.4%) 0.074
Body mass index (kg/m2) 16.9 (14.0–19.7) 18.3 (16.6–21.5) 0.023
Hugh-Jones classification (III/IV/V) 1/18/23 2/25/6 0.005
Pre-existing lung disorder 0.001
Pulmonary fibrosis 20 (47.6%) 7 (21.2%)
Bronchiolitis obliterans 13 (31.0%) 5 (15.2%)
Pulmonary arterial hypertension 3 (7.1%) 2 (6.1%)
Other 6 (14.3%) 19 (57.5%)
Preoperative pulmonary hypertension 8 (19.0%) 3 (9.1%) 0.328
Preoperative condition
NPPV 2 (4.8%) 0 (0.0%) 0.191
Ventilator-dependent 5 (11.9%) 1 (3.0%) 0.160
Type of transplant 0.001
Bilateral 33 (78.6%) 14 (42.4%)
Single 9 (21.4%) 19 (57.6%)
Use of cardiopulmonary support 42 (100.0%) 17 (51.5%) <0.0001
Blood product volume administered intraoperatively (l) 5.7 (3.2–7.0) 2.6 (1.3–4.6) 0.001
Total ischaemic time (min) 154 (135–197) 452 (391–530) <0.0001
Graft FVC (% of predicted FVC of the recipient) 60.0 (51.3–74.6) – –
Patients were considered to have pulmonary hypertension when the systolic pulmonary artery pressure (estimated by transthoracic echocardiography) was
≥60 mmHg.
LDLLT: living-donor lobar lung transplantation; CLT: cadaveric lung transplantation; NPPV: non-invasive positive pressure ventilation; FVC: forced vital
capacity.
Figure 1: Prevalence and severity of PGD from immediately after reperfusion to
72 h after ICU admission. PGD: primary graft dysfunction; ICU: intensive care
unit; CLT: cadaveric lung transplantation; LDLLT: living-donor lobar lung trans-
plantation; Trep: immediately after final reperfusion; T0: at ICU arrival; T12–T72:
12–72 h after ICU admission.
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Impact of Grade 3 primary graft dysfunction on
secondary outcome measures
We assessed the effect of Grade 3 PGD on the length of ICU and
hospital stays and hospital mortality (Table 3). LDLLT patients
with Grade 3 PGD at Trep had significantly longer stays in ICU
than those without (P = 0.005). Moreover, hospital mortality was
significantly higher in LDLLT patients with Grade 3 PGD at Trep
than in those without. In contrast, Grade 3 PGD at Trep was not
associated with duration of ICU or hospital stay, or hospital mor-
tality, in CLT patients.
Multivariate analysis of ventilator-free days in
patients with living-donor lobar lung
transplantation
To determine the predictive value of Grade 3 PGD at Trep in
LDLLT patients independently of pretransplant morbidity or trans-
plant procedure type, multiple linear regression was performed,
adjusting for the presence of pretransplant morbidity; specifically
in age, body mass index, dyspnoea according to Hugh-Jones clas-
sifications (3–4 and 5), preoperative pulmonary hypertension, pre-
operative ventilator dependence; operative variables, specifically
single-lung transplant, total donor graft ischaemic time and
volume of intraoperatively administered blood products.
Following backward elimination, variables that remained in the
final model and that were found to be confounders were pre-
operative pulmonary hypertension, preoperative ventilator de-
pendence and volume of intraoperatively administered blood
products. Multivariate linear regression analysis revealed that
Grade 3 PGD at Trep was significantly associated with decreased
VFDs in LDLLT patients independently of pre- and intraoperative
variables (P = 0.01; Table 4).
Characteristics associated with Grade 3 primary
graft dysfunction at Trep in living-donor lobar
lung transplantation
Finally, we assessed patient characteristics associated with the de-
velopment of Grade 3 PGD at Trep in LDLLT patients (Table 5).
Patients with Grade 3 PGD at Trep were significantly younger than
those without (P = 0.005); of the 11 patients with Grade 3 PGD at
Trep, 7 (63.6%) were children under 15 years old. Of note, six of
nine single-lobe transplanted recipients developed Grade 3 PGD
at Trep. The median graft FVC in the 7 children with PGD Grade 3
at Trep was 73.3% and five had a graft FVC of 55% or more. No sig-
nificant association was observed between graft FVC and the
development of Grade 3 PGD at Trep.
DISCUSSION
We investigated the incidence and time course of PGD following
LDLLT and assessed the impact of Grade 3 PGD on outcomes in
LDLLT patients. Analysis of our cohort revealed the following: (i)
the incidence of Grade 3 PGD at 48 or 72 h after ICU admission
was similar between LDLLT and CLT patients; (ii) the onset of
Grade 3 PGD after LDLLT tended to be earlier than after CLT; and
(iii) Grade 3 PGD at Trep was a significant predictor of fewer VFDs
during the initial 28 postoperative days, prolonged postoperative
ICU stay and increased hospital mortality in LDLLT patients.
Since the publication of the ISHLT standardized definition and
grading of PGD, the incidence of Grade 3 PGD at 48 or 72 h after
CLT has been reported to be between 10 and 20%, and the inci-
dence rate of Grade 3 PGD at any time point during the initial 72
postoperative hours has been reported as 30% [19]. The inci-
dence of Grade 3 PGD after LDLLT observed in our study (33.3% at
Figure 2: Time series analysis of PGD. (A) Timing of Grade 3 PGD onset; associ-
ation between Grade 3 PGD at Trep and PGD grades at 48 or 72 h after ICU ad-
mission in living-donor lobar (B) and cadaveric (C) lung transplantation. PGD:
primary graft dysfunction; ICU: intensive care unit; LDLLT: living-donor lobar
lung transplantation; CLT: cadaveric lung transplantation; Trep: immediately
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any time point from Trep to T72 and 16.7% at T48 or T72) was not
found to significantly differ from those after CLT and was similar to
previously reported incidences in CLT. However, the time course
of PGD significantly differed between LDLLT and CLT patients. In
CLT, more than half of patients with Grade 3 PGD first developed
Grade 3 PGD at T0 or T12, corroborating a previous study that
reported a significant variation in the PaO2=FIO2 ratio within the
first 12 postoperative hours with stabilization thereafter [20].
In contrast, the majority of patients developing Grade 3 PGD
following LDLLT developed Grade 3 PGD at Trep, with a few
patients found to develop Grade 3 PGD at T0 or later.
The difference in the time course of PGD between LDLLT and
CLT patients might be explained by differing mechanisms under-
lying the development of PGD in these patient populations. PGD
is characterized by pulmonary oedema with diffuse alveolar
damage associated with ischaemia and reperfusion of lung grafts
[3, 11]. Factors thought to contribute to the injury of lung grafts
from cadaveric donors during brain death or prolonged
Table 2: Impact of severe PGD at each time point on VFDs
Trep T0 T12 T24 T48 T72
LDLLT
Grade 0–2 21 (13–25) 21 (10–25) 22 (9–25) 21 (6–25) 21 (6–25) 21 (6–25)
Grade 3 0 (0–10) 0 (0–7) 0 (0–9) 0 (0–8) 0 (0–8) 0 (0–10)
P 0.001 0.002 0.002 0.004 0.004 0.007
CLT
Grade 0–2 24 (17–26) 25 (18–26) 25 (18–26) 24 (18–26) 24 (18–26) 24 (17–25)
Grade 3 18 (8–25) 18 (7–24) 6 (0–17) 14 (4–18) 3 (0–15) 3 (0–5)
P 0.245 0.029 0.001 0.030 0.008 0.030
PGD: primary graft dysfunction; VFDs: ventilator-free days; Trep: immediately after reperfusion; T0: at ICU arrival; T12–T72, 12–72 h after ICU admission;
LDLLT: living-donor lobar lung transplantation; CLT: cadaveric lung transplantation.
Table 3: Impact of Grade 3 PGD at Trep on outcomes according to transplantation procedure
Grade 3 PGD at Trep (n = 11) Grade 0–2 PGD at Trep (n = 31) P-value
LDLLT
Time to discharge (days)
From ICU 20 (16–27) 12 (8–14) 0.005
From hospital 99 (60–114) 81 (58–91) 0.093
Hospital mortality 3 (27.3%) 1 (3.2%) 0.020
Grade 3 PGD at Trep (n = 9) Grade 0–2 PGD at Trep (n = 24) P-value
CLT
Time to discharge (days)
From ICU 9 (7–13) 7 (5–11) 0.741
From hospital 46 (43–76) 53 (43–90) 0.971
Hospital mortality 1 (11.1%) 1 (4.2%) 0.457
PGD: primary graft dysfunction; at Trep: immediately after reperfusion; LDLLT: living-donor lobar lung transplantation; CLT: cadaveric lung transplantation;
ICU: intensive care unit.
Table 4: Multivariate linear regression analysis of VFDs during the initial 28 postoperative days in LDLLT patients
Variables Regression coefficient 95% CI P-value
Grade 3 PGD at Trep −8.48 −14.82 to −2.13 0.010
Ventilator-dependent −13.27 −22.09 to −4.46 0.004
Preoperative pulmonary hypertension −5.72 −12.25 to 0.81 0.084
Blood volume administered intraoperatively (l) −0.83 −1.59 to −0.06 0.035
VFDs: ventilator-free days; LDLLT: living-donor lobar lung transplantation; PGD: primary graft dysfunction; at Trep: immediately after reperfusion; CI:
confidence interval.
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mechanical ventilation include pneumonia, aspiration, blood
transfusion, haemodynamic instability and ventilation-associated
injury. Moreover, graft ischaemic time is much greater in CLT
patients than in LDLLT patients. We therefore propose that
patients who underwent CLT were at higher risk of severe ischae-
mia–reperfusion injury. In contrast, grafts from LDLLT donors are
not exposed to infection or mechanical ventilation and have a
shorter ischaemic time. We discussed the concept of ‘a small but
perfect graft’ previously [2], and size mismatch has been shown to
be the predominant cause of graft dysfunction in LDLLT [15]. The
results of this study may suggest that graft dysfunction due to size
mismatch can be assessed at Trep, whereas graft dysfunction due
to ischaemia–reperfusion injury cannot be assessed until develop-
ment of dysfunction at later time points.
Appropriate size matching between donors and recipients is
crucial in LDLLT. The use of a graft too small for a recipient may
result in poor ventilation (functional size matching), and the use of
a graft too large for the recipient hemithorax may result in high
airway resistance, atelectasis and haemodynamic instability at
chest closure (anatomical size matching) [15]. As is presented in
Table 5, paediatric patients receiving single-lobe transplantation
were apparently at greater risk of developing severe PGD. This
finding corroborates our previous report [15] suggesting that bilat-
eral LDLLT is a better option when two living donors are available.
Our study revealed that Grade 3 PGD at Trep is a useful prog-
nostic marker following LDLLT. As PGD grades at very early time
points predict lung transplant outcomes, measurement of this par-
ameter may allow earlier intervention in a specific group of
patients. In contrast, Grade 3 PGD at Trep was not found to be a
significant prognostic marker following CLT. As the PaO2=FIO2 ratio
dynamically changes during the early post-transplant period in
CLT, the use of later time points may be more appropriate for the
assessment of graft function. Previous studies have demonstrated
that Grade 3 PGD at T48–T72 has construct validity for determin-
ing long-term outcomes and concurrent lung injury markers [14,
21]; therefore, the assessment of PGD on postoperative day 2 or 3
may have greater utility.
In the multivariate analysis of VFDs in LDLLT patients, preopera-
tive mechanical ventilation, preoperative pulmonary hypertension
and the volume of intraoperatively administered blood products
remained in the final model. Each of these factors has been impli-
cated as a predictive factor in previous studies of lung transplant
outcomes in CLT patients [22–25]. These may represent prognostic
factors common to both LDLLT and CLT.
The major limitations of this study were its retrospective design
and small sample size. Data collected in this study were derived
from a single institution. Heterogeneity in procedures (e.g. single
and bilateral lung transplantation) and pretransplant status made
it difficult to interpret the results; future studies are warranted to
confirm our results by taking these variables into account.
Ventilator settings potentially influenced PaO2=FIO2 . Despite these
limitations, our data provide new information regarding the post-
operative respiratory management of LDLLT patients.
In conclusion, this study found that the incidence of severe (Grade
3) PGD after LDLLT did not significantly differ from the incidence of
severe PGD following CLT. In LDLLT patients, the onset of severe
PGD tended to be earlier than that in CLT patients. Severe PGD at
Trep was a significant predictor of fewer VFDs, a longer postoperative
ICU stay and increased hospital mortality in LDLLT patients.
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We read with great interest the manuscript by Mizota et al. describing the inci-
dence and timing of primary graft dysfunction (PGD) in living donor lobar lung
transplantation (LDLLT) and comparing this to cadaveric lung transplantation (CLT)
[1]. The authors found that in LDLLT patients, the onset of severe PGD tended to be
earlier and that severe PGD immediately after reperfusion was a significant predictor
of postoperative morbidity and mortality.
Donor-to-recipient lung size mismatch in LDLLT is a common occurrence. We have
conducted a series of investigations on the associations between donor-to-recipient
lung size mismatch and outcomes after lung transplantation in CLT-recipients and
have found the following:
(a) Undersizing (as assessed by the donor-to-recipient predicted total lung capacity
ratio [pTLCratio]) is an independent risk factor for PGD in bilateral CLT [2];
(b) In a study of bilateral CLT, tidal volumes during mechanical ventilation (when
tidal volumes were indexed to donor predicted body weight, as an estimate of
the actual size of the allograft), were substantially higher (and potentially in-
jurious), if the allograft was undersized compared to oversized allografts [2,3];
(c) Undersizing is an independent predictor of one-year mortality following CLT [4].
In the study by Mizota et al., lung size matching was assessed by calculating graft
forced vital capacity. The majority of patients undergoing LDLLT with grade 3 PGD
at reperfusion had a single-lung lobar transplant (55%) and were <15 years old
(64%) [1]. The authors reported that there was no association between graft forced
vital capacity and the development of grade 3 PGD at reperfusion in LDLLT.
However, it is not clear how the authors accounted for the impact of single-lung
LDLLT and paediatric age in their assessment of lung size mismatch. It would be
helpful, if the authors could provide pTLCratio data (actual donor pTLC trans-
planted via lobar transplant/pTLC of the recipient) and the association between
pTLCratio and PGD.
A consequence of ischaemia reperfusion injury is endothelial cell leak. Pulmonary
oedema formation following reperfusion from this mechanism is transient and most
apparent in the first 5–15 minutes of reperfusion. If an allograft is undersized below a
critical threshold regarding the size of the pulmonary vascular bed, it is possible that
this could lead to pulmonary oedema formation immediately following reperfusion.
To avoid this, either a larger vascular surface area (larger allograft) would need to be
transplanted, or an intra- and postoperative strategy that uses extracorporeal support
to unload the undersized allograft would be needed, until the endothelial cell leak is
resolved.
Furthermore, we recommend lung protective mechanical ventilation with low tidal
volumes (6 ml/kg predicted body weight) and positive end expiratory pressure for
the post-lung transplant period. In our opinion, the tidal volume needs to be based
on donor-characteristics (donor predicted body weight, as a parameter of actual allo-
graft size), rather than based on recipient characteristics to avoid potentially injurious
ventilator settings for the recipients of undersized allografts [5].
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